CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DAKT1E17KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
CPIK3CAN345KPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibRay et al., 2016
CBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 Y253FPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 E255KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 D276GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 E355GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 E355GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 H396RPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F486SPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CABL1L298VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F359CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 L384MPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 Q300RPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 N331SPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 L364PPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 L387FPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 D421GPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 E453KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 E453APredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 P480APredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBRAFExon 15 MutationPredictiveSupportsResistanceGastrointestinal Stromal TumorRegorafenib AnhydrousGeorge et al., 2012
CABL1V379IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 A397PPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
DBRAFG596RPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerVemurafenibYang et al., 2012
CABL1C475VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 N336SPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibJenkins et al., 2015
BATMUnderexpressionPredictiveSupportsSensitivity/ResponseStomach CancerOlaparib,PaclitaxelBang et al., 2015
CVHLG123fs (c.369_375delGACACAC)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseOng et al., 2007
CDICER1E1813QOncogenicSupportsOncogenicitySertoli-Leydig Cell TumorHeravi-Moussavi et al., 2012
CDICER1D1709GOncogenicSupportsOncogenicityGranulosa Cell TumorHeravi-Moussavi et al., 2012
CDICER1D1709NOncogenicSupportsOncogenicityGlandular Pattern Ovarian Yolk Sac TumorHeravi-Moussavi et al., 2012
CDICER1D1709EOncogenicSupportsOncogenicityGlandular Pattern Ovarian Yolk Sac TumorHeravi-Moussavi et al., 2012
BPTCH1MutationPredictiveSupportsSensitivity/ResponseCancerVismodegibHainsworth et al., 2018
CVHLL184P (c.551T>C)DiagnosticSupportsPositiveRenal Cell CarcinomaBailly et al., 1995
CVHLG104= (c.312C>G)PredisposingN/AVon Hippel-Lindau DiseaseOlschwang et al., 1998
CVHLS65L (c.194C>T)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGallou et al., 2001
Page 92 of 96
PreviousNext